Kyverna Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $355.03M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | During market hours | – | $-0.63 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | During market hours | – | $-0.66 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | During market hours | – | $-0.80 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | During market hours | – | $-0.85 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | During market hours | – | $-0.97 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | – | $-1.03 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | During market hours | – | $-0.67 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | During market hours | – | $-1.12 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 26, 2024 | During market hours | – | – | – |
Press releases
Announcements Kyverna Therapeutics filed with the SEC
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
Other events · EX-99.1 to Form 8-K
AAN April 22, 2026 ©2026 Kyverna Therapeutics, Inc.
Regulation FD disclosure · EX-99.1 to Form 8-K
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
Regulation FD disclosure · EX-99.1 to Form 8-K
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
Results of operations · Executive or director change · EX-99.1 to Form 8-K
PRESS RELEASE, DATED DECEMBER 17, 2025
Material agreement · Other events · EX-99.1 to Form 8-K
(KYV-101) in Stiff Person Syndrome (SPS) December 15, 2025 ©2025 Kyverna Therapeutics, Inc.
Regulation FD disclosure · EX-99.1 to Form 8-K
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
Regulation FD disclosure · EX-99.1 to Form 8-K
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Interim Data for KYSA-6 Phase 2
Regulation FD disclosure · EX-99.1 to Form 8-K
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of
Regulation FD disclosure · EX-99.1 to Form 8-K
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JUNE 30, 2025
Executive or director change · Other events · EX-99.1 to Form 8-K
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY KYVERNA THERAPEUTICS, INC., DATED JANUARY 13, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
KYVERNA THERAPEUTICS, INC. PRESENTATION - PIONEERING CAR T IN AUTOIMMUNE DISEASES, JANUARY 2025
Regulation FD disclosure · EX-99.2 to Form 8-K
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
PRESS RELEASE, DATED OCTOBER 21, 2024
Executive or director change · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 16, 2024
Executive or director change · Other events · EX-99.1 to Form 8-K
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Kyverna’s KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K